REG - Polarean Imaging PLC - Result of General Meeting

Polarean ImagingAnnouncement

15/12/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251215:nRSO6387La&default-theme=true

RNS Number : 6387L  Polarean Imaging PLC  15 December 2025

15 December 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

Result of General Meeting

Information on Matched Bargain Facility to assist shareholders

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical technology
company and global leader in functional lung imaging using hyperpolarised
Xenon MRI, announces that at the general meeting of the Company ("General
Meeting") held earlier today, all resolutions were duly passed on a poll.

 

Details of the poll results are set out below:

 

 Resolution Number  Name                                                                    Votes for    % of votes for  Votes against  % of votes against  Votes withheld*
 1                  Cancellation Resolution                                                 534,365,742  80.71%          127,743,445    19.29%              2,347,443

 2                  Re-registration and adoption of new articles of association Resolution  534,390,927  80.71%          127,740,655    19.29%              2,325,048

 

*Note: A 'vote withheld' is not a vote under English law and is not counted in
the calculation of votes 'for' or 'against' a resolution.

Valid proxy instructions were received in respect of 664,456,630 Ordinary
Shares representing approximately 55.05% of the issued share capital of the
Company.

 

The total number of Ordinary Shares in issue as at 15 December 2025 is
1,207,032,781.

 

The full text of the Resolutions proposed and passed at the General Meeting
can be found in the circular of the Company containing, inter alia, the notice
of General Meeting, which was published on 14 November 2025 (the "Circular")
and is available on the Company's website here. Capitalised terms used but not
defined in this announcement shall have the same meaning given to such terms
in the Circular.

 

AIM Cancellation

 

Following approval by Shareholders at the General Meeting, the admission of
the Ordinary Shares to trading on AIM will be cancelled. The Cancellation is
expected to take place at 7:00 a.m. on 23 December 2025 and, accordingly, the
last day of dealings in Ordinary Shares on AIM is expected to be 22 December
2025.

 

Re-registration as a private company

 

In accordance with the passing of Resolution 2, the Company will re-register
as a private limited company and adopt new articles of association, which is
expected to take place by 12 January 2026.

 

Matched Bargain Facility

 

The Company has made arrangements for the Matched Bargain Facility to assist
Shareholders to trade in the Ordinary Shares from the date of Cancellation.
The Matched Bargain Facility will be provided by J P Jenkins, which is an
appointed representative of Prosper Capital LLP, which is authorised and
regulated by the UK Financial Conduct Authority. Under the Matched Bargain
Facility, Shareholders or persons wishing to acquire or dispose of Ordinary
Shares will be able to leave an indication with J P Jenkins, through their
stockbroker, of the number of Ordinary Shares that they are prepared to buy or
sell and the price at which they are prepared to do so. In the event that J P
Jenkins is able to match that order with an opposite sell or buy instruction,
it would contact both parties and then effect the bargain (trade). Upon the
Cancellation becoming effective, the Matched Bargain Facility will commence,
and details will be made available to Shareholders on the Company's website
(www.polarean.com (http://www.polarean.com) ). It should be noted, however,
that there is no guarantee as to the liquidity such a facility would afford
the Ordinary Shares post Cancellation.

 

Shareholders will continue to be able to hold their shares in uncertificated
form (i.e. in CREST) and should check with their existing stockbroker whether
they are willing or able to trade in unquoted shares.

 

The Matched Bargain Facility is intended to operate for a minimum of twelve
months after Cancellation. The current intention is that it will continue
beyond that time, but Shareholders should note it could be withdrawn at short
notice and therefore inhibit Shareholders' ability to trade the Ordinary
Shares. The provision of a matched bargain facility will be kept under review
by the Board and, in determining whether to continue to offer a matched
bargain facility, the Company shall consider expected (and communicated)
shareholder demand for such a facility, as well as the composition of the
Company's register of members and the costs to the Company and shareholders.

 

The indicative pricing for the Ordinary Shares, as well as the transaction
history, will be available on the JP Jenkins website at https://jpjenkins.com/
(https://jpjenkins.com/) .

 

Enquiries:

 

 Polarean Imaging plc                                www.polarean.com (http://www.polarean.com) / www.polarean-ir.com
                                                     (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer                                   Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                               Tel: +44 (0)20 7710 7600
 Nicholas Moore / Fred Walsh / Brough Ransom / Ben Good

 Walbrook PR                    Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Marcus Ulker     Mob: +44 (0)7876741001 / +44 (0)7867984 082

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform.

 

For the latest news and information about Polarean, please visit the website
at www.polarean.com (http://www.polarean.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMQELFFELLBFBL



            Copyright 2019 Regulatory News Service, all rights reserved